EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Tarsus Pharmaceuticals, Inc. (TARS) had EBIT Margin of -33.55% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$78.33M |
|
$-25.12M |
|
$5.21M |
|
$73.12M |
|
$104.61M |
|
$-26.28M |
|
$1.16M |
|
$-25.12M |
|
$-25.12M |
|
$-25.12M |
|
$-25.12M |
|
$-25.12M |
|
$-25.12M |
|
$-26.28M |
|
$-27.00M |
|
39.34M |
|
39.34M |
|
$-0.64 |
|
$-0.64 |
|
| Balance Sheet Financials | |
$480.77M |
|
$2.79M |
|
$19.98M |
|
$500.75M |
|
$86.31M |
|
$71.98M |
|
$71.98M |
|
$158.29M |
|
$342.46M |
|
$334.37M |
|
$342.46M |
|
42.00M |
|
| Cash Flow Statement Financials | |
$-20.65M |
|
$-34.94M |
|
$136.56M |
|
$97.38M |
|
$178.35M |
|
$80.97M |
|
$6.93M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.57 |
|
-- |
|
-- |
|
0.17 |
|
0.21 |
|
93.35% |
|
-33.55% |
|
|
EBIT Margin |
-33.55% |
-- |
|
-32.07% |
|
-32.07% |
|
$-21.24M |
|
-- |
|
-- |
|
-- |
|
0.16 |
|
1.93 |
|
1.22 |
|
73.71 |
|
-7.34% |
|
-7.51% |
|
-5.02% |
|
-6.06% |
|
$8.15 |
|
$-0.54 |
|
$-0.52 |
|